Company / SG&A Expense
RAPT Therapeutics, Inc. SG&A Expense History
FY2018-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$28.9M
FY2024
5-year range
$12.8M / $28.9M
FY2020-FY2024
Trend
+10.8%
vs FY2023
Sector context
#183 of 212
Health Care
What the data says
RAPT Therapeutics, Inc.'s sg&a expense of $29M is lower than 86% of companies in the Health Care sector (FY2024). SG&A Expense has increased for 6 consecutive years, from $5M in FY2018 to $29M in FY2024.
Based on SEC 10-K filings.
$29M in FY2024 with a 5-year CAGR of +27.1%.
Increased from $20M to $29M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +21.7%
- 5-Year CAGR
- +27.1%
- 10-Year CAGR
- -
Sector benchmark
Top 14% in Health CareTop 14% of 212This company $28.9M Sector average $722.9M
▼
-96.0% below sector average
Key checks
Key Insights
- RAPT Therapeutics, Inc.'s sg&a expense has grown for 6 consecutive years.
- 5-year CAGR of +27.1%, indicating consistent growth.
- In FY2024, sg&a expense increased 10.8% year-over-year.
- Ranks #183 out of 212 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.38 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $28.9M | +10.8% |
| FY2023 | $26.1M | +28.8% |
| FY2022 | $20.2M | +26.2% |
| FY2021 | $16.0M | +25.6% |
| FY2020 | $12.8M | +46.5% |
| FY2019 | $8.7M | +68.3% |
| FY2018 | $5.2M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026